<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="915">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on October 07, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04405843</url>
  </required_header>
  <id_info>
    <org_study_id>ScDi823</org_study_id>
    <nct_id>NCT04405843</nct_id>
  </id_info>
  <brief_title>Efficacy of Ivermectin in Adult Patients With Early Stages of COVID-19</brief_title>
  <official_title>Randomized, Placebo Controlled, Double Blind Clinical Trial to Evaluate the Efficacy of Molecule D11AX22 in Adults Patients From Valle Del Cauca, Colombia With Early Stages of SARS COV2 / COVID-19</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Centro de Estudios en Infectogía Pediatrica</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Centro de Estudios en Infectogía Pediatrica</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Double blind, placebo controlled, randomized clinical trial to evaluate the efficacy of
      ivermectin in preventing progression of disease in adult patients with early stages of
      COVID-19
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 14, 2020</start_date>
  <completion_date type="Anticipated">December 14, 2020</completion_date>
  <primary_completion_date type="Anticipated">November 2020</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Time to event</measure>
    <time_frame>21 days</time_frame>
    <description>Time until deterioration of 2 or more points in an ordinal 7 points scale.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Clinical condition on day 2</measure>
    <time_frame>On day 2 (± 1 day) after randomization</time_frame>
    <description>Clinical condition in an ordinal scale of 7 points, on day 2. Higher scores indicate worse outcomes</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical condition on day 5</measure>
    <time_frame>On day 5 (± 1 day) after randomization</time_frame>
    <description>Clinical condition in an ordinal scale of 7 points, on day 5. Higher scores indicate worse outcomes</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical condition on day 8</measure>
    <time_frame>On day 8 (± 1 day) after randomization</time_frame>
    <description>Clinical condition in an ordinal scale of 7 points, on day 8. Higher scores indicate worse outcomes</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical condition on day 11</measure>
    <time_frame>On day 11 (± 1 day) after randomization</time_frame>
    <description>Clinical condition in an ordinal scale of 7 points, on day 11. Higher scores indicate worse outcomes</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical condition on day 15</measure>
    <time_frame>On day 15 (± 1 day) after randomization</time_frame>
    <description>Clinical condition in an ordinal scale of 7 points, on day 15. Higher scores indicate worse outcomes</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical condition on day 21</measure>
    <time_frame>On day 21 (± 1 day) after randomization</time_frame>
    <description>Clinical condition in an ordinal scale of 7 points, on day 21. Higher scores indicate worse outcomes</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of subjects with additional care</measure>
    <time_frame>21 days</time_frame>
    <description>Proportion of subjects who require hospitalization, use of supplementary oxygen for &gt;24 hours or ICU admission</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of subjects who die</measure>
    <time_frame>From randomization up to 21 days</time_frame>
    <description>Proportion of subjects who die</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of additional care</measure>
    <time_frame>21 days</time_frame>
    <description>Duration of supplementary oxygen, hospitalization, ICU stay</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse events</measure>
    <time_frame>21 days</time_frame>
    <description>Proportion of subjects who develop solicited adverse events</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of subjects who discontinue intervention</measure>
    <time_frame>21 days</time_frame>
    <description>Proportion of subjects who required discontinuation of the trial due to adverse events</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">400</enrollment>
  <condition>COVID-19</condition>
  <arm_group>
    <arm_group_label>Ivermectin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Ivermectin, 300 micrograms / kg, once daily for 5 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Substance with similar physical and organoleptic characteristics as ivermectin, without the active drug ingredient</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ivermectin Oral Product</intervention_name>
    <description>Ivermectin oral suspension, 6 mg/mL</description>
    <arm_group_label>Ivermectin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Substance with similar physical and organoleptic characteristics as ivermectin, without the active drug ingredient</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  At least 18 years of age

          -  Confirmed SARS-CoV-2 by RT-PCR or antigen detection in a Colombian NIH-approved
             laboratory

          -  Beginning of symptoms in the past 7 days

          -  Mild disease

          -  Informed consent

        Exclusion Criteria:

          -  Preexisting liver disease

          -  Hypersensitivity to ivermectin

          -  Participants in other clinical trials for therapies against COVID-19

          -  Severe pneumonia

          -  Pregnant or breastfeeding women

          -  Concomitant use of warfarin, erdafitinib or quinidine

          -  Use of ivermectin in the 48 hours prior to randomization

          -  Inability to obtain a blood sample needed to assess liver transaminases

          -  Elevation of transaminases &gt;1.5 times the normal level

          -  Participant whose first contact with the study personnel occurs between days 5 and 7
             and at that time manifests significant and progressive resolution of COVID-19 related
             signs and symptoms
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Eduardo López-Medina, MD MSc</last_name>
    <role>Principal Investigator</role>
    <affiliation>Scientific Director of Centro de Estudios en Infectología Pediátrica --CEIP--</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Eduardo López-Medina, MD MSc</last_name>
    <phone>+57 315 612 9266</phone>
    <email>eduardo.lopez@ceiponline.org</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Elizabeth Toro, MD</last_name>
    <email>elizabeth.toro@ceiponline.org</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Centro de Estudios en Infectología Pediátrica</name>
      <address>
        <city>Cali</city>
        <state>Valle</state>
        <zip>12345</zip>
        <country>Colombia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Eduardo López-Medina, MD MSc</last_name>
      <phone>+573156129266</phone>
      <email>eduardo.lopez@ceiponline.org</email>
    </contact>
  </location>
  <location_countries>
    <country>Colombia</country>
  </location_countries>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>May 23, 2020</study_first_submitted>
  <study_first_submitted_qc>May 26, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">May 28, 2020</study_first_posted>
  <last_update_submitted>August 31, 2020</last_update_submitted>
  <last_update_submitted_qc>August 31, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">September 2, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ivermectin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

